What are your top takeaways from ISC 2025?

1. We had hoped that medium-sized vessel occlusions (MeVOs) would respond to endovascular thrombectomy (EVT) as do large vessel occlusions (LVOs), but several trials show a lack of benefit of current EVT technology for MeVOs. Patients with MeVOs (and more distal occlusions) remain a target for finding...

EVT treatment for Medium Vessel Occlusion (MeVO) – ISC 2025 presentation of 3 trials

In three trials that tackled the issue of extension of EVT to acute ischemic stroke due to more distal vessel occlusions, EVT was not better and possibly slightly harmful, as compared to the best medical care. The ES...

A contrarian answer, but I stand by it. My takeaway was that our research and efforts continue to focus on the wrong problems.

Since the 2015 thrombectomy trials, there have been no breakthroughs in stroke care of comparable benefit. We keep reshuffling the same therapies or refining them, resultin...